1,130
Participants
Start Date
May 24, 2024
Primary Completion Date
May 15, 2027
Study Completion Date
July 15, 2027
RMC-6236
Oral tablet
mFOLFOX6 regimen
IV infusion
bevacizumab
IV infusion
mFOLFIRINOX regimen
IV infusion
cetuximab
IV infusion
gemcitabine
IV infusion
nab-paclitaxel
IV infusion
RMC-9805
Oral Tablet
RECRUITING
Columbia University Medical Center, New York
RECRUITING
Memorial Sloan Kettering Cancer Center Main Campus, New York
RECRUITING
Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
Duke University Medical Center, Durham
RECRUITING
Mayo Clinic Cancer Center, Jacksonville
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
University of Cincinnati Medical Center, Cincinnati
RECRUITING
Mayo Clinic, Rochester
RECRUITING
The University of Kansas Clinical Research Center, Westwood
RECRUITING
Nebraska Cancer Specialists, Omaha
RECRUITING
Stephenson Cancer Center, Oklahoma City
RECRUITING
NEXT Oncology Dallas, Irving
RECRUITING
Baylor College of Medicine, Houston
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Huntsman Cancer Institute, University of Utah, Salt Lake City
RECRUITING
Mayo Clinic Hospital, Phoenix
RECRUITING
Ironwood Cancer and Research Centers, Chandler
RECRUITING
HonorHealth Research Institute, Scottsdale
RECRUITING
University of Colorado Hospital-Anschutz Cancer Pavilion, Aurora
RECRUITING
Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles
RECRUITING
UCLA Hematology/Oncology- Santa Monica, Los Angeles
RECRUITING
UC San Diego Moores Cancer Center, La Jolla
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Atlantic Health System, Morristown
Revolution Medicines, Inc.
INDUSTRY